eIF4E Phosphorylation Drives ASD-like Phenotypes via Mitochondrial Dysfunction and Translational Dysregulation in a VPA Mouse Model

Researchers have identified a potential therapeutic pathway for addressing autism spectrum disorder (ASD)-like behaviors in mice, focusing on the regulation of protein synthesis. A study published March 7, 2026, in the Journal of Physiology and Biochemistry details how correcting overactivation of the eIF4E protein can rescue imbalances in the translatome – the set of messenger RNAs being actively translated into proteins – and alleviate core behavioral symptoms associated with ASD. The research, conducted using C57BL/6 mice purchased from SPF (Beijing) Biotechnology Co., Ltd. , offers a novel avenue for investigating potential treatments for the complex neurodevelopmental condition.

Valproic Acid Model and eIF4E’s Role

The study utilized a mouse model of ASD induced by valproic acid (VPA), a common anti-epileptic drug known to increase the risk of autism in children exposed to it in utero. Researchers administered VPA to pregnant mice on gestational day 12.5, observing subsequent ASD-like behaviors in the offspring. The team found that VPA exposure led to a downregulation of PPARα in the livers of the mice, disrupting redox homeostasis and triggering inflammatory cascades. Crucially, the research pinpointed eIF4E, a key regulator of mRNA translation, as being overactivated in these mice. This overactivation, in turn, contributed to the translatome imbalance and the manifestation of ASD-like behaviors.

Restoring Translational Balance

The core of the study involved manipulating eIF4E activity. Researchers created modified versions of the eIF4E protein – one that couldn’t be phosphorylated (S209A) and another that mimicked phosphorylation (S209D) – and introduced them into cells. They discovered that restoring proper regulation of eIF4E phosphorylation was key to correcting the translational imbalances. Specifically, reducing eIF4E overactivation helped restore normal protein synthesis rates and alleviate symptoms in the VPA-exposed mice.

Behavioral Improvements and Underlying Mechanisms

Behavioral tests revealed significant improvements in mice where eIF4E activity was corrected. These included improvements in social interaction, reduced self-grooming (a repetitive behavior often seen in ASD models), and enhanced cognitive function. The researchers used a three-chamber test, open-field test, and elevated zero-maze test to assess these behaviors. Further investigation revealed that modulating eIF4E activity impacted several key signaling pathways. The team observed that exercise, a known regulator of lipid metabolism, could activate PPARα, inhibit NF-κB (a pro-inflammatory molecule), and enhance the expression of antioxidant enzymes like HO-1 and SOD1. This, in turn, regulated redox balance and reduced inflammation.

Deep Dive into Protein Synthesis and Mitochondrial Function

To understand the mechanisms at play, the researchers employed sophisticated techniques like polysome profiling and RNA sequencing. Polysome profiling revealed how mRNA molecules distribute across different ribosomal complexes, indicating their translation rates. RNA sequencing allowed them to identify specific genes whose expression was altered by eIF4E manipulation. These analyses showed that correcting eIF4E activity restored normal translation of genes involved in synaptic function and neuronal development.

The study also highlighted the role of mitochondrial dysfunction in the VPA-induced ASD model. Mitochondrial complex activity assays and transmission electron microscopy revealed impaired mitochondrial function and morphology in the brains of affected mice. Correcting eIF4E activity improved mitochondrial respiration and restored normal mitochondrial structure. This was further supported by LC-MS/MS analysis, which identified differentially expressed proteins involved in mitochondrial function.

eFT508 as a Potential Therapeutic Agent

The researchers tested the drug eFT508 (Tomivosertib), an mTOR inhibitor, as a potential therapeutic intervention. Mice treated with eFT508 showed improvements in behavioral symptoms, suggesting that targeting the mTOR pathway – which is downstream of eIF4E – could be a viable therapeutic strategy. The drug was administered via intraperitoneal injection, with four daily doses starting at postnatal week 3.

Implications for Autism Research and Drug Development

This research provides compelling evidence for the involvement of eIF4E-mediated translational dysregulation in the pathogenesis of ASD. The findings suggest that restoring translational balance could be a promising therapeutic approach. Although the study was conducted in mice, it offers valuable insights for future research aimed at developing targeted therapies for individuals with ASD. The identification of eFT508 as a potential therapeutic agent warrants further investigation, although clinical trials are needed to assess its safety and efficacy in humans.

The study builds on previous research highlighting the importance of protein synthesis in brain development and function. For example, a 2022 study published in Embo Reports demonstrated the role of eEF2 in promoting excitatory synaptic transmission and social novelty behavior. The current study expands on these findings by identifying eIF4E as a key regulator of translational control in the context of ASD.

Next Steps and Ongoing Research

Researchers are now focused on further elucidating the specific molecular mechanisms by which eIF4E regulates protein synthesis in the brain. They are also investigating the potential of other mTOR inhibitors and exploring novel strategies for targeting the eIF4E pathway. Future studies will involve larger sample sizes and more comprehensive behavioral assessments to validate the findings and assess the long-term effects of eIF4E modulation. The team also plans to investigate the role of genetic factors in eIF4E dysregulation and explore personalized treatment approaches based on individual genetic profiles.